EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)

Heart Rate-Corrected QT Interval Dynamics Following Antidepressant Switching from Escitalopram to High-Dose Venlafaxine: Cardiac Safety Insights from the Early Medication Change Cohort

Jan Engelmann iD, Andreas Solheid, Stefanie Wagner, Blanca P Quesada Ocete, David P Herzog, Nadine Dreimüller, Kathrin M Kachel, Marianne B Müller, André Tadic, Dieter F Braus, Christoph Hiemke, Klaus Lieb

Pharmacopsychiatry · 01.09.2026 · 59 (05) · 320-327

DOI: 10.1055/a-2793-9711 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift Pharmacopsychiatry, erschienen am 01.09.2026. Verfasst von Jan Engelmann und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Psychotherapy, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany. Hauptthemen laut MEDLINE: Antidepressive Agents, Antidepressive Agents, Second-Generation, Citalopram, Escitalopram. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Bundesministerium für Bildung und Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Electrocardiographic changes indicating a significantly increased risk of adverse cardiac effects, such as heart-rate corrected QT interval prolongation, are rare during antidepressant treatment; however, systematic analyses are lacking. Therefore, our study aimed at investigating the relationship between heart-rate corrected QT interval changes and both dosage and serum levels of escitalopram and venlafaxine in a well-characterized study sample. Two hundred seven depressed patients received escitalopram (10–20 mg/d) for 4 weeks. Non-responders were switched to high-dose venlafaxine (150–375 mg/d) for an additional 4 weeks of treatment. Serum concentrations were measured weekly and electrocardiograms were recorded at baseline, day 28 and day 56. Risk factors for heart-rate corrected QT interval prolongation were included as covariates in the analysis. Escitalopram did not significantly affect heart-rate corrected QT intervals. Switching to high-dose venlafaxine resulted in a significant increase of mean QT intervals from day 29 to day 56 (p=0.007), more pronounced in men (interaction p=0.038). Heart-rate corrected QT interval prolongation occurred in 5% of patients after escitalopram and 12% after venlafaxine; notably, 12 patients experienced critical prolongations, all with higher rates of known risk factors. No correlation between serum concentrations and heart-rate corrected QT intervals were observed. Our findings indicate that escitalopram does not affect heart-rate corrected QT intervals, whereas venlafaxine is associated with a modest but significant heart-rate corrected QT interval prolongation, particularly in males. Although infrequent, critical prolongations highlight the need for individualized risk assessment, especially in patients with risk factors. The lack of correlation with serum concentrations suggests that pharmacokinetic monitoring alone may not reliably predict cardiac risk. Our results underscore the importance of electrocardiogram monitoring with attention to sex-specific and clinical risk profiles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antidepressive AgentsAntidepressive Agents, Second-GenerationCitalopramEscitalopramHeart RateLong QT SyndromeVenlafaxine HydrochlorideAdultFemaleHumansMaleMiddle AgedCohort StudiesDose-Response Relationship, DrugElectrocardiographyDrug Substitution

Substanzen

Antidepressive AgentsAntidepressive Agents, Second-GenerationCitalopramEscitalopramVenlafaxine Hydrochloride

Autor:innen und Institutionen

  • Department of Psychiatry and Psychotherapy, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
  • Department of Psychiatry and Psychotherapy & Focus Program Translational Neuroscience, Translational Psychiatry, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
  • Center for Cardiology, Department of Cardiology II/Electrophysiology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
  • Department of Psychiatry, Psychosomatics and Psychotherapy, Dr. Fontheim Mentale Gesundheit, Liebenburg, Germany.
  • Department of Psychiatry and Psychotherapy, Vitos Rheingau, Eltville, Germany.

ORCID-Profile: Jan Engelmann

Förderung

  • Bundesministerium für Bildung und Forschung

Zitieren

APA

Engelmann, J., Solheid, A., Wagner, S., Quesada Ocete, B. P., Herzog, D. P., Dreimüller, N., Kachel, K. M., Müller, M. B., Tadic, A., Braus, D. F., Hiemke, C., & Lieb, K. (2026). Heart Rate-Corrected QT Interval Dynamics Following Antidepressant Switching from Escitalopram to High-Dose Venlafaxine: Cardiac Safety Insights from the Early Medication Change Cohort. Pharmacopsychiatry, 59(05), 320-327. https://doi.org/10.1055/a-2793-9711

Vancouver

Engelmann J, Solheid A, Wagner S, Quesada Ocete BP, Herzog DP, Dreimüller N, et al. Heart Rate-Corrected QT Interval Dynamics Following Antidepressant Switching from Escitalopram to High-Dose Venlafaxine: Cardiac Safety Insights from the Early Medication Change Cohort. Pharmacopsychiatry. 2026;59(05):320-327. doi:10.1055/a-2793-9711

BibTeX
@article{Engelmann2026,
  author = {Engelmann, Jan and Solheid, Andreas and Wagner, Stefanie and Quesada Ocete, Blanca P and Herzog, David P and Dreimüller, Nadine and Kachel, Kathrin M and Müller, Marianne B and Tadic, André and Braus, Dieter F and Hiemke, Christoph and Lieb, Klaus},
  title = {Heart Rate-Corrected QT Interval Dynamics Following Antidepressant Switching from Escitalopram to High-Dose Venlafaxine: Cardiac Safety Insights from the Early Medication Change Cohort},
  journal = {Pharmacopsychiatry},
  year = {2026},
  volume = {59},
  number = {05},
  pages = {320--327},
  doi = {10.1055/a-2793-9711}
}
Kostenlos starten →